免疫检查点抑制剂相关感染:免疫失调所致的新兴并发症
本文综述免疫检查点抑制剂(ICI)治疗癌症过程中感染并发症的新认识。作者提出将感染分为免疫抑制所致与免疫失调所致两类,后者可在未使用免疫抑制剂时由ICI诱发,以失调性炎症免疫反应为特征。文章总结相关证据并提出新的分类框架。
要点
- ICI治疗中感染可与免疫相关不良反应(irAE)表现相似,需注意鉴别。
- 使用糖皮质激素等免疫抑制剂治疗irAE可导致机会性感染。
- 部分感染可在无免疫抑制治疗时由ICI诱发,特征为失调性炎症免疫反应。
核心结论
- 部分感染可由ICI在无免疫抑制治疗情况下诱发,特征为失调性炎症免疫反应,作者建议称为免疫失调所致免疫治疗感染。
研究设计与样本
- 本文为综述,总结关于癌症免疫治疗背景下感染现象的新兴证据并提出新的分类框架。
主要发现
- ICI治疗中irAE常见且可类似感染;以糖皮质激素等免疫抑制剂治疗irAE可导致机会性感染。
- 新兴报告显示部分感染可在无免疫抑制治疗时由ICI诱发,与多数已报告病例不同。
临床怎么用
- 在癌症免疫治疗中评估感染时,应同时考虑免疫抑制所致与免疫失调所致两类感染,并注意与irAE鉴别。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune checkpoint inhibitors (ICIs) have revolutionised cancer treatment. However, immune-related adverse events (irAEs) are a common side effect which can mimic infection. Additionally, treatment of irAEs with corticosteroids and other immunosuppressant agents can lead to opportunistic infection, which we have classed as immunotherapy infections due to immunosuppression. However, emerging reports demonstrate that some infections can be precipitated by ICIs in the absence of immunosuppressive treatment, in contrast to the majority of reported cases. These infections are characterised by a dysregulated inflammatory immune response, and so we propose they are described as immunotherapy infections due to dysregulated immunity. This review summarises the rapidly emerging evidence of these phenomena and proposes a new framework for considering infection in the context of cancer immunotherapy.
引用
- Morelli T, Fujita K, Redelman-Sidi G, et al. Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy. Thorax. 2021. PMID: 34607905. doi:10.1136/thoraxjnl-2021-217260
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。